{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277988","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.905299+00:00","generated_at":"2026-05-16T20:54:52.350002+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme issues $1.5B in convertible notes; repurchases $1.02B of existing notes","bullets":["Issued $750M 0% convertible notes due 2031 and $750M 0.875% notes due 2032; net proceeds ~$1.47B.","Used ~$1.02B to repurchase 0.25% notes due 2027 and 1.00% notes due 2028 via private transactions.","Entered capped call transactions ($182.7M) to limit dilution; cap price $136.78 vs conversion price $87.20.","Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277988","json":"https://secwatch.observer/filing/0001193125-25-277988.json","markdown":"https://secwatch.observer/filing/0001193125-25-277988.md","text":"https://secwatch.observer/filing/0001193125-25-277988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:54:52.350002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39299b5f85f3387bb8b6a71138eebe8f85593e3b","claim":"HALOZYME THERAPEUTICS, INC. incurred convertible notes of $1,500.0 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0% maturing due 2031.","evidence_excerpt":"completed its previously announced sale of $1,500.0 million aggregate principal amount convertible senior notes, consisting of (i) $750.0 million of 0% Convertible Senior Notes due 2031","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm","confidence":1.0,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$1,500.0 million aggregate principal amount"},{"label":"Counterparty","value":"The Bank of New York Mellon Trust Company, N.A."},{"label":"Rate","value":"0%"},{"label":"Maturity","value":"due 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"4023164b88656f389fbe724296629805c43ea1f8","claim":"HALOZYME THERAPEUTICS, INC. incurred convertible notes of $750.0 million in aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0.875% maturing due 2032.","evidence_excerpt":"(ii) $750.0 million in aggregate principal amount of 0.875% Convertible Senior Notes due 2032","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm","confidence":1.0,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$750.0 million in aggregate principal amount"},{"label":"Counterparty","value":"The Bank of New York Mellon Trust Company, N.A."},{"label":"Rate","value":"0.875%"},{"label":"Maturity","value":"due 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}